Biohit Oyj: Notification Pursuant to Chapter 9, Section 10 of the Finnish Securities Markets Act
Biohit Oyj Stock Exchange Release, 28 October 2026 at 11:15 a.m. (EET)
Biohit Oyj has on 28 October 2026 received a notification pursuant to Chapter 9, Section 5 of the Finnish Securities Markets Act, according to which the holding of Biohit Healthcare (Hefei) Co., Ltd in Biohit Oyj has fallen below the 20 percent threshold of shares and the 5 percent threshold of votes. The thresholds were crossed downward on 27 October 2026 when Biohit Healthcare (Hefei) Co., Ltd divested 650,000 series A shares in Biohit Oyj. Biohit Healthcare (Hefei) Co., Ltd holds a total of 2,795,415 series B shares in Biohit Oyj. These holdings represent 18.38 percent of all shares and 3.90 percent of all votes in the company.
| % of shares and votes | Total number of shares and votes in the company | |
| Holding after the threshold was crossed | 18.38% of shares and 3.90% of votes | 15,205,593 shares and 71,740,093 votes |
| Holding reported in the previous flagging notification (if previously disclosed) | 22.67% of shares and 22.02% of votes |
| Series | Shares and votes (pcs) | % of shares and votes | ||
| Direct (AML 9:5) | Indirect (AML 9:6 and 9:7) | Direct (AML 9:5) | Indirect (AML 9:6 and 9:7) | |
| Series A share | 0 shares and 0 votes | – | 0.00% of shares and 0.00% of votes | – |
| FI0009005482 Series B share | 2,795,415 shares and 2,795,415 votes | – | 18.38% of shares and 3.90% of votes | |
| Total | 2,795,415 shares and 2,795,415 votes | 18.38% of shares and 3.90% of votes | ||
Biohit Oyj has two share classes. Each Series A share carries 20 votes, and each Series B share carries one vote. Biohit Oyj has a total of 2,975,500 Series A shares and 12,230,093 Series B shares. The total number of shares is 15,205,593, representing a total of 71,740,093 votes.
Additional information
Jussi Hahtela
CEO, Biohit Oyj
Tel. +358 50 383 5948
investor.relations@biohit.fi
www.biohit.fi
Biohit in brief
Biohit Oyj is a Finnish biotechnology company that operates internationally. Biohit’s mission is Innovating for Health – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki and has subsidiaries in Italy and the United Kingdom. Biohit’s series B share (BIOBV) is listed on Nasdaq OMX Helsinki in the Small Cap/Healthcare group.